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Abstract 
This paper investigates management and organization factors which may 
enhance the effectiveness of biomedical research and pharmaceutical 
innovation. The study consists of 222 survey questionnaires returned by 
senior scientific staff of academic hospitals and large health research 
institutes in the Netherlands and the main R&D laboratories of innovative 
pharmaceutical companies in Europe, and 47 in-depth interviews with 
professors, institute directors and R&D directors. The results suggest that 
pharmaceutical companies are more positively engaged in consistent control 
than are academic research laboratories, with health research institutes 
taking up an intermediate position. It is concluded that a well-balanced 
combination of personnel, administrative and external control is needed to 
improve effectiveness in universities, institutes and companies alike. © 1997 
Elsevier Science Ltd 
1. INTRODUCTION 
The achievements of today's medicine are impress- 
ive. SFnallpox, cholera and diphtheria, diseases which 
devastated populations, are now rare or nonexistent 
in most parts of the world. The search for 'magic bul- 
lets', which kill germs without destroying host cells, 
has led to a constant stream of antimicrobial medi- 
cations. However, as their bacterial targets have 
developed resistance, physicians have entered a 
never-ending race to stay ahead of adaptation. Phys- 
icians are therefore in need of a continuous stream of 
new and innovative drugs. Increased knowledge of 
the biochemical and physiological background of dis- 
eases has enabled pharmaeutics to provide them with 
a large spectrum of gradually safer and more effective 
drugs. Increasingly, research efforts are being put into 
more complex therapeutic areas for which no easy 
solution is forthcoming. 
A study by Capron (1994), including 135 compa- 
nies in the chemical, (tele)communication, computer 
and aviation industries, under which 22 were branded 
ethical drug firms, revealed the pharmaceutical indus- 
try as one of the most technology driven. In the phar- 
maceutical industry, even more than in other high- 
tech industries, competitive power is based on innov- 
ative capacity. The pharmaceutical R&D process 
takes more than a decade and is carried out in a num- 
ber of laboratories located in different countries. It 
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includes laborious searching for NCEs (new chemical 
entities with assumed therapeutic efficacy) in drug 
discovery, drug targeting and toxicology testing in 
pharmaceutical development and the succeeding clini- 
cal testing on healthy volunteers and patients (Omta 
et al., 1994a,b; Omta, 1995). Basic, applied and 
industrial research into drug discovery and drug 
design have become increasingly interwoven. Taylor 
(1994) calculates that the innovative pharmaceutical 
industry spends on average 10% to 20% of its total 
R&D budget on sponsorships and collaborative 
research with universities and institutes. 
The present study has been conducted in 71 
research laboratories in academic hospitals, health 
research institutes and innovative pharmaceutical 
companies. It investigates the management and 
organization factors which may enhance research 
effectiveness, and the instruments which should be 
used to do so. 
2. 'IliEORE'IICAL MODEL 
The innovation management model developed in 
this study is based upon the concept that effectiveness 
stands, via positive and negative feedback and feed- 
forward loops, in dynamic equilibrium with the qual- 
ity of management control (control exerted by the 
research management, the senior scientific staff of the 
laboratory). Management control in turn is considered 
to be a function of organizational flexibility and con- 
trol capacity. Organizational flexibility refers to the 
ability of the organization to adapt to changing situ- 
ations. Control capacity refers to the competence of 
the research management to achieve these adap- 
tations, given the level of organizational flexibility. A 
highly competent research management may reach a 
high adaptation level, even if the organization is rela- 
tively inflexible, whereas a less competent research 
management may fail, even if the organization as a 
whole is highly flexible (see equations 1 and 2). 
E =f(MC) + IX (1) 
where E = effectiveness, MC = management control, 
Ix = residual variation; 
MC =f(OF, CC) + /x (2) 
where MC = management control, OF = organiza- 
tional flexibility, CC = control capacity and /x = 
residual variation. 
Fisscher (1991) emphasizes that, for management 
control to be effective, system-technical factors (such 
as phasing and structuring of research projects, setting 
of targets in terms of time, money and specifications) 
and socio-dynamic factors (directed towards enhance- 
ment of the motivation of the scientific staff) should 
be combined. Therefore a control mix of system-tech- 
nical and socio-dynamic factors is tested in this study. 
The study design is based on the concept of 'con- 
text comparison'. If, for a certain phenomenon 
(management control) in one overall context 
(biomedical research and pharmaceutical innovation) 
but in three different (sub-) contexts (universities, 
institutes and company laboratories), consistent 
relationships with outcome are found, this phenom- 
enon is considered to be fundamental for these 
relationships and may therefore be generalized to 
related contexts in other technology fields. 
3. OPERAllONALIZAIION OF VARIABLES 
3.1 Management control 
In management practice, control is often narrowly 
defined, including monitoring and correcting (often 
used in financial terms to mean budget control). The 
system-theoretical concept of control, used in this 
study, originates from a much broader paradigm, 
namely: any method of (goal)-directed influence (de 
Leeuw, 1990). This broader paradigm enables control 
to be applied to a variety of forms of organizational 
processes, such as power processes, organizational 
learning, and changing of the organizational structure. 
Management control can be divided further into sys- 
tem, process and external control (see Table 1). 
System control refers to control over the personnel 
and material resources of the laboratory. It is divided 
into personnel and resources control. Personnel con- 
trol refers to the 'objective' quality of the reward sys- 
tem (organizational flexibility: number of tangible and 
intangible incentives, career policy etc.) and the com- 
petence of management to react to changing situations 
(control capacity: e.g. pace and manner of conducting 
reorganizations). The challenge of research manage- 
ment is to create the conditions conducive to meeting 
the corporate goals of scientific performance (system- 
technical performance) as well as the scientists' need 
for satisfaction and motivation (socio-technical 
performance). Several examples of effective reward 
systems for researchers have been reported (Badawy, 
1988). In this study the incentives mentioned by Jauch 
(1976) are used to operationalize personnel control. 
Resources control refers to the adequacy of the 
resources (such as laboratory devices, budget and 
space) to facilitate the conductance of the tasks of the 
laboratory, and the absence of administrative con- 
straints. It combines organizational flexibility and 
control capacity at the operational level. 
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TABLE 1. Operationalization of management control 
System control 
Personnel control (12 items) 
Assessment of the effectiveness of personnel policy; Likert scales, higher 
values indicate a more positive assessment, e.g. 
• cases concerning appointment, promotion and dismissal 
• primary and secondary working conditions (salary level, stocks, use of 
company car etc.) 
• good reputation of the organization or the research leader 
• career planning within the organization or as a step-up towards other 
organizations 
• recognition, e.g. possibilities for publishing, extra payment for 
extraordinary research efforts and training facilities 
• pace and manner of conducting reorganizations 
Adequacy (resources control: 3 items) 
Assessment of the ability to conduct the primary tasks of the laboratory; 
Likert scales: 
• adequacy of the research budget and laboratory equipment 
Administrative control (resources control: 2 items) 
Assessment of the organization's ability to adapt to changing situations; 
Likert scales: 
• speed of reallocation, appointment and procurement procedures 
Process control 
Planning (2 items) 
The perceived importance of short- and middle-range planning by higher 
management as related to day4o-day research activities 
Frequency of research meetings (research process communication, 1 item) 
Frequency of communication in research meetings 
Attendancy mix (research process communication, 4 items) 
Attendance at research meetings: whether only scientific staff or also support 
staff, scientists from other laboratories, other R&D phases and/or marketing 
and production; Likert scales 
External control 
International communication (3 items) 
• frequency of contacts with scientists and physicians, and with colleagues 
at international conference and workshops 
• scale and scope of joint research projects with universities, institutes and 
companies 
Contractor communication (2 items) 
Frequency of contacts with industrial and government contractors 
Process control is divided into planning and 
research process communication. Planning includes 
the perceived importance of strategic, tactical and 
operational planning by the top management for day- 
to-day research work. It relates to the goal 
setting/accounting relationship between research 
management and top management. Research process 
communication, in contrast, relates to the control 
capacity of the research management, the gradual 
transition from 'hands on' to 'hands off' supervision, 
measured by the frequency of research meetings and 
the attendancy mix. The latter refers to the level of 
lateral and cross-functional communication in indus- 
try. External control refers to the position of the lab- 
oratory in the international scientific network and in 
universities and institutes, referring also to the net- 
work with industrial and government contractors. 
3.2 EffeciJveness (TaMe 2) 
"Organizational effectiveness relates to the 
accomplishment of the cooperative purpose ... When 
a desired end is attained we shall say that the action 
is effective" (Anthony, 1965, p. 27). In universities 
and institutes the output of the research units is div- 
ided into output directed to the scientific community 
(research effectiveness) and output directed to indus- 
trial and govemment contractors (user effectiveness). 
Research effectiveness is measured by the number of 
scientific papers published per full-time equivalent 
(fte) scientific staff. It is considered as a quantitative 
indicator of the ability to conduct basic research. This 
is combined with the indicator for the apparent use 
of the research results by the scientific community 
(effective output according to Hazeu and Spangen- 
berg (1991)), the citation score. 2 User effectiveness is 
TABLE 2. Operationalization of effectiveness 
Research effectiveness (universities and institutes) 
The average number of papers published annually by scientists of the 
research unit, in international scientific journals per scientist from 1988 to 
1991 
User effectiveness (universities and institutes) 
The average number of reports published annually per scientist of the 
research unit for industrial or governmental contractors from 1988 to 1991 
Citation score (universities and institutes) 
The average number of citations per scientific paper, published from 1985 to 
1987, in the three years following publication. Self-citations and citations by 
research unit members are omitted. The number of citations is divided by the 
average number of citations of all papers published in that period in the 
same joumals (journal weighed) and in the same (sub-)disciplines (weighed 
for discipline) 
Number of patents (industry: innovative effectiveness) 
The average annual number of patents for new chemical compounds, 
submitted worldwide with first priority date from 1985 to 1991 (Pharmdoc 
Section of the Word  Patents Index Database of Derwent Publications; 
process and formulation patents have not been considered) per US$10 
million R&D expenditure in discovery 
Length of development (industry: innovative effectiveness) 
The average time span between patenting of the lead compound and launch 
of the registered drug on the prescription drug market (years-~)~ 
Operating profit margin (industry: industrial effectiveness) 
Operating result/revenues. Operating result: result after deduction of normal 
operating charges and before financial income and expenses, taxes etc. 
Revenues: net turnover including other operating revenues, change in stocks 
and capitalized costs 
~Estimation of research directors of the time-span between patenting and launch 
of anti-hypertensive and anti-ulcer drugs. These drugs were chosen because the 
development process is neither relatively short (antibiotics) nor very long (anti- 
psychotics). In five companies the reported length was checked for ten drugs 
which were launched after 1987. In all cases the findings proved to agree. 
2 Extensive literature exists about  the shor tcomings  o f  citation analysis  
(Moed et al., 1992). The main points o f  cri t icism concern  the differ- 
ences in the kinds of  journa l  published and  the differences across 
(sub-)disciplines in the number  o f  researchers,  the number  o f  refer- 
ences per  paper  and  the t ime lag between publ ishing and the citation 
opt imum. In addition, self- and  peer  g roup  citation are notable prob-  
lems. An  at tempt was  made to solve these problems by  excluding self- 
citations and by weighing for  the average number  o f  citations o f  the 
papers  in the journals  in which  they were  published and for  the average 
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measured by the number of reports published annually 
per scientist for industrial and government contrac- 
tors. It is considered to reflect the ability of the 
research unit to conduct applied research. 
In industry, effectiveness is measured at the level 
of the research process itself (innovative 
effectiveness) and at the company level (industrial 
effectiveness). Innovative effectiveness relates prim- 
arily to the control capacity of the research manage- 
ment, whereas industrial effectiveness is primarily 
related to the top management level and thus to 
organizational flexibility. To assess innovative effec- 
tiveness two measures are used. The number of pat- 
ents per annual R&D expenditure in discovery is used 
as an indicator of the effectiveness of the discovery 
phase. 3 The length of the development process is used 
as an indicator of the effectiveness in the development 
phase, because time-to-market is one of the most 
important factors determining the profitability of a 
pharmaceutical company (Redwood, 1987; Taggart, 
1993; de Wolf, 1987). 
Innovation, although essential, is not enough to 
reach the ultimate goal of attaining long-term profit- 
ability for a company. It is obvious that without an 
adequate marketing and sales force an innovative drug 
will never reach its full profit potential. Vos (1989) 
analyses two companies which jointly developed a 
drug. The successive marketing effort was done sep- 
arately. The firm with the best R&D-marketing inter- 
face clearly got the highest return on R&D invest- 
ment. Therefore, the operating profit margin is used as 
an indicator of industrial effectiveness (see Table 2). 
4. HYPOTHESES 
4.1 Comparison of the slxata 
Two important sources of differences between the 
strata of universities, institutes and companies can be 
distinguished, influencing the level of management 
control. Firstly, the goals of the organizations are dif- 
ferent. Generally speaking, the primary goal of a uni- 
versity is to perform basic research, that of an institute 
number of citations of the papers in the (sub)-discipline(s) involved 
in the time-span of publishing. 
3 There are a number of problems involved in the use of patent stat- 
istics; for instance, the possible difference in patenting policy (timing 
and scope) between companies (Basberg, 1987; Pavitt, 1988), the dif- 
ference between leading (real innovative), defensive and follow on 
(me-too) patenting, as well as the increased importance of in- and out- 
licensing in order to attain a complete patent portfolio (see, for 
example, Fitzgerald, 1992; Gambardella, 1992). In a previous paper 
of the authors these problems are discussed in more detail (Omta et 
aL, 1994). 
is to perform applied research, and that of a pharma- 
ceutical company is to maintain long-term profitabil- 
ity by conducting R&D superior to its competitors. In 
the sequence basic research, applied research and 
R&D, environmental and task uncertainty is assumed 
to decrease (see, for example, Cohen and March, 
1974; Zeldenrust, 1989). Research activities are 
thought to be rather uncertain in the sense that task 
outcomes are not repetitive or predictable. To reduce 
the level of uncertainty, researchers must keep in con- 
stant communication with colleagues in order to keep 
up with the state-of-the-art in their research field. It 
is hypothesized that international communication and 
research process communication will be more inten- 
sive in universities and institutes than in company lab- 
oratories. Regarding international communication, the 
differences might be slight, because in a 'science- 
based industry' such as pharmaceutics the building of 
an international scientific network is essential (see, for 
example, Gambardella, 1992; Taylor, 1994). Contacts 
with outside contractors will be very intensive in both 
universities and institutes, because of the increased 
importance of external funding due to budget 
retrenchments. 
Secondly, there are important differences originat- 
ing from the profit or not-for-profit background of the 
research organizations. All universities and most 
institutes are part of the public sector, and therefore 
subject to state (e.g. personnel, purchasing and 
construction) regulations and budget management 
restrictions. The personnel complement is largely 
fixed through tenure and contractual provisions. Life- 
time appointment, combined with a strong legal 
status, limits the possibilities of decisive intervention 
in situations of conflict. Also, reallocation and job 
rotation are more difficult to implement. Furthermore, 
in profit organizations the feedback on a reduction in 
results is very direct. The operating profit margin is 
very compelling, because of the permanent threat of 
being overtaken by a competitor. In companies, 
administration and R&D staff have corresponding 
interests: maintaining the profitability and thereby the 
competitive position of the company. Therefore, it is 
expected that the scientific staff in pharmaceutical 
companies will set higher value upon system control 
and planning than the staff in universities and insti- 
tutes. Table 3 summarizes these predictions. 
4.2 Companng high and low performers 
The basic idea behind this paper is that manage- 
ment control is fundamental for success in biomedical 
research and pharmaceutical innovation. The main 
hypothesis is that for a number of management con- 
trol variables the above-average performers will show 
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TABLE 3. Hypothesized relative strength of management control in the three strata 
Universities Institutes Companies 
System control +_ -~ 
Process control 
planning - +_ 4 
frequency/attendancy mix + + 
External control 
international communication + + -~ 
contractor communication + + 
+ Comparatively highest strength of the management control variable at issue. 
_+ Moderate strength. 
Lowest strength. 
* Not measured. 
higher scores than the below-average performers 
(median split). It is expected that robust and consist- 
ent relations between management control and effec- 
tiveness will be found for the effectiveness indicators, 
which reflect the primary goals, and weak and incon- 
sistent relations for those indicators which reflect the 
secondary goals of the organizations. Not all manage- 
ment control variables are equally important, of 
course. One of the main objectives of this paper is 
to indicate which are the most critical for success in 
biomedical research and pharmaceutical innovation. 
5. METHODS OF DATA COLLECTION AND DATA 
ANALYSIS 
Semi-structured interviews were held with pro- 
fessors, institute directors and R&D directors (mostly 
members of the Board of Directors). In the interviews 
information was obtained about research management 
in general, and issues to be included in the survey 
questionnaires were collected. The interviews were 
taped and the protocols were sent to the interviewees 
for approval. 
Standardized survey questionnaires, consisting of 
126 precoded questions based on Likert 5-point 
scales, were sent to the research staff of the participat- 
ing laboratories. They combined factual information 
(such as number of staff, research budget and output) 
with views and judgements about different aspects of 
management control (such as systems of remuner- 
ation, the flexibility of the organization to react to 
changing situations and the intensity of internal and 
external (network) communication; see Table 1). 
Before the data collection started, the questionnaires 
were tested on a sample of twelve biomedical 
researchers from the Faculty of Science, and four 
retired staff members from the pharmaceutical and 
chemical industry. Their comments were incorporated 
into the questionnaires. After data collection, all 
scales were recalculated in such a way that a higher 
number indicates a more positive assessment of the 
item concerned. Cronbach's a was calculated for the 
individual subscales to find out whether they corre- 
sponded with the variables defined, and to check fc~r 
the internal consistency of the items supposed to mea- 
sure a single concept. In all cases Cronbach's a was 
sufficiently high (>0.62) to warrant confidence in the 
internal consistency. 
6. DATACOLLECTION 
In order to warrant objectivity, the effectiveness 
indicators were obtained by use of bibliometric meas- 
ures and checked by the research management con- 
cerned. Different statistical methods were used to 
relate the management control variables to the effec- 
tiveness indicators. Substantive conclusions were sup- 
ported by all statistical techniques. The multivariate 
associations were assessed by 4Thought, a multilayer 
feed forward neural network which uses an 
exponential sum formula based upon series expansion 
to calculate the node's output value (Box 1). Neural 
network models are based on pattern recognition and 
therefore produce non-parametric models. This 
enables the multi-variate comparison of variables 
operationalized at different measurement levels. 
The empirical study was conducted in 40 biomed- 
ical research units in eight academic hospitals and in 
17 research units in five health research institutes in 
the Netherlands. This was combined with a European 
survey of 14 large pharmaceutical companies with 
discovery and/or pharmaceutical development labora- 
tories in Great Britain, Germany, France, Belgium 
and the Netherlands. Nine companies are among the 
top 20 companies ranked according to the 1991 
world-wide branded ethical drug sales. The other five 
are among the top 50 pharmaceutical companies. Pat- 
ent analysis revealed that from 1985 to 1991 3874 
licensees in total submitted pharmaceutical patents to 
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Box 1 
Artificial neural networks are used in quite different areas such as design support, process management, (medical) diagnostics, marketing (data base mining), 
speech and visual memory and predicting of exchange rates, and prices of shares and options. Neural networks are based upon the functioning of the human 
brain. The basic element of the neural network is the artificial neuron (called a node), which can be considered a functional abstraction of the biological 
neuron. The human central nervous system consists of more than 100 billion of interconnected neurons. The information of one neuron is passed through to 
thousands of others, which in turn spread it further. Learning in the human brain consists of a continuous readjustment of the relative strength of  the signals 
sent between the different neurons. 
x(2) > y 
In analogy to this, an artificial neural network consists of different layers of neurons working in parallel. Inside a node the weighted (w~ n) input signals 
(x~ ,) are summed (E), and an algorithm is used to calculate the node's output signal (y) to the next layer in the network. In the neural network 4-Thought, 
which was used in this study, the algorithm is an exponential sum formula based upon series expansion (Hoptroff et al., 1991). The neural network uses the 
independent variables to build a model of  the dependent variable(s). 
The actual 'learning process' consists of continuously readjusting the weighing factors in the network. In every step of the learning process a neural 
network compares a pair of  input and output values, which differ in a constant factor from each other (in 4-Thought a factor of 1.05). For the next step, that 
model is chosen in which the sum-of-squares error between the current and the desired mapping performance is most rapidly reduced. At the end of the 
learning process the model with the highest overall explained variance is selected. There is a threat of "over-fitting'. An 'over-fit' model fits too perfectly to 
the data set, ignoring the natural variability ( 'noise')  in the data. To avoid this problem, a neural network divides the data into two groups, a 'training' set 
and a 'test '  set. In 4-Thought the training set consists of 80% and the test set the remaining 20% of the data. The neural network builds a model on the 
training set data and tests this model on the data of the test set. 
The "learning' process is only allowed to proceed as long as the errors in the training set and the test set are both dropping. Initially, both the errors for 
the training and the test set fall. When the noise in the data begins to dominate the learning process, the error for the test set starts to rise again, while the 
error in the training set continues to fall. At this point the learning process is stopped and the resulting model is presented. Statistically, it means the 
selection of a biased fit to the training set data based on the optimum fit to the test set data (Hoptroff et al., 1991). 
A neural network in which the information flows in one direction only (such as 4-Thought) is called a feedforward neural network. In a recurrent 
network, connections within one layer and with the neurons in the preceding layers of the network occur as well. 
the European authorities. 4 The strong innovative 
capacity was illustrated by the fact that the 14 compa- 
nies together submitted 25% of all the pharmaceutical 
patents in this period. In total, 278 questionnaires 
were sent to the research management in universities, 
72 in institutes and 59 in industrial laboratories. Of 
these questionnaires, 142 were returned from univer- 
sities, 44 from institutes and 38 from industrial lab- 
oratories, a response rate of 51%, 61% and 64%, 
respectively. Structured interviews were held with 16 
professors, nine institute directors and 22 R&D direc- 
tors. 
7. RESULTS 
Table 4 shows that the average sales volume of 
branded ethical drugs amounted to $3.4 billion in 
1991, with an operating profit margin of 24%. As 
could be expected of a science-based industry, the 
average R&D expenditure is high, about 15% of the 
total sales volume. About 25% of the total R&D 
expenditure was spent on discovery, which resulted 
4 T h e  n u m b e r  o f  l i censees  is ac tual ly  less,  because  m o s t  c o m p a n i e s  
use  d i f f e ren t  l i censee  n a m e s  and  addresses .  
TABLE 4. Descriptive statistics of pharmaceutical companies (n = 14) 
Mean Standard 
deviation 
Annual sales of ethical drugs ($m) 3372 1913 
R&D expenditure ($m) 540 248 
discovery ($m) 126 70 
development ($m) 390 209 
Number of patents (per $10m) 5.3 2.6 
Length of development (years) 9.3 2.1 
Operating profit margin (%) 23.6 I 1.2 
in about five patents per $10 million annually. The 
development phase has a long duration: it took the 
companies on average more than nine years to bring 
an NCE to the market. 
Table 5 shows that about 20 staff members work 
in a laboratory. The running costs in biomedical 
research, being part of 'big science' (Spiegel-ROsing 
and de Solla Price, 1977), are rather high. The 
material costs per researcher amount from more than 
US$10000 in universities to nearly US$20000 in 
institutes. The percentage external funding of the 
research laboratories in this study doubled from 
around 20% in 1986 to nearly 40% in 1991. It has 
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TABLE 5. Descriptive statistics of research units in universities (n = 40) and 
institutes (n = 17; mean and F-value) 
Universities Institutes F-value 
Staff (fte) 19.9 19.5 0.01 
Material resources (US$/fte) I 1330 19630 2.53 
External funding (%) 39 37 0.14 
Research effectiveness 
(sc papers/fte) 1.22 0.87 6.25*** 
User effectiveness (reports/fte) 0.30 0.65 3.37** 
Citation score 1.16 1.59 7.96"* * 
F~,ncway AN()VA: *19 < 0.1, **p < 0.05, ***p < 0.01 
tutes and companies. The scientific staff members in 
companies are, on average, more positive about the 
effectiveness of personnel policy than their colleagues 
in universities and institutes. Although large differ- 
ences could be established between scientists in the 
different companies, their average judgement of 
remuneration, career possibilities and recognition was 
clearly more positive. In universities especially, the 
average assessment of the personnel policy situation 
and the adequacy of resources is judged negatively 
(the average assessment is below 3 on the Likert 5- 
point scale). 
often been argued that if more than one-third of the 
resources of a laboratory stemmed from external 
funding the (programmatic) continuity would be at 
risk. For most of the laboratories this is already the 
normal situation. 
As expected, the research effectiveness is higher in 
universities, whereas the user effectiveness is twice 
as high in institutes. The scientists publish (and 
supervise) more than one scientific paper per year. 
Calculated per PhD student, this is approximately 2 
to 2.5 papers. According to citation measures, Dutch 
biomedical research scores above the world average. 
In both universities and institutes the number of 
citations per paper scores above the world average for 
the (sub)-discipline(s) involved. It is interesting to 
note that the number of papers per scientist is higher, 
but the number of citations per paper is fewer, in uni- 
versities as compared to institutes. The scientific pap- 
ers of the more experienced researchers in institutes 
are apparently more penetrating than those of young 
PhD students, which are written under huge 'publish 
or perish' pressure in the limited time-span for gradu- 
ation. 
Table 6 shows that clear differences are found in 
the level of management control in universities, insti- 
The other variables of system control--adequacy of 
resources and administrative control--are also judged 
more positively in companies. The estimated pace of 
the administrative procedures is nearly twice as high 
as in universities. Monitoring of the scientific network 
is also more intensive and participation in inter- 
national conferences is significantly higher. 
Researchers in institutes take up an intermediate pos- 
ition between universities and companies on all the 
variables of system and external control. In contrast 
to this, research process control is significantly more 
intensive in universities and institutes than in compa- 
nies, and the frequency of research meetings and the 
attendancy mix are significantly higher. 
Table 7 shows the multivariate associations of 
management control and effectiveness. Concerning 
universities and institutes, the best models are found 
for research effectiveness in universities and user 
effectiveness in institutes, with a total explained vari- 
ance of 37% and 63%, respectively. In both cases per- 
sonnel control, administrative control and inter- 
national communication count for the total of the 
explained variance. No model was found for user 
effectiveness in universities and only a weak one for 
research effectiveness in institutes. It is interesting to 
note that the same three variables of management 
TABLE 6. Comparison of management control in universities, institutes and pharmaceutical companies (mean and F-value) 
Management control Universities Institutes Companies F-value 
n= 142 n = 4 4  n = 3 8  
System control 
personnel control 2.52 3.09 3.33 6.96*** 
adequacy 2.54 2.89 3.56 3.65** 
administrative control 2.00 2.41 3.48 8.96*** 
Process control 
planning 3.62 3.64 3.78 0.06 
frequency 4.25 4.49 3.07 10.50'** 
attendancy mix 2.81 2.80 2.37 3.37** 
External control 
international communication 2.54 3.06 3.46 3.64** 
contractor communication 2.84 2.59 na 0.09 
na = not applicable; F ,~ , y  ANOV :̂ *P < 0.1, **p < 0.05, ***p < 0.01 
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T A B L E  7. Percentage  exp la ined  var iance  of  e f fec t iveness  by m a n a g e m e n t  control  
Un ive r s i t i e s  Inst i tutes C o m p a n i e s  
n = 4 0  n = 1 7  n = 1 0  
re ue cs re ue cs pn dl o p m  
System control 
personne l  cont ro l  
adequacy  
admin i s t r a t ive  cont ro l  
Process control 
p l ann ing  
f requency  
a t tendancy mix  
External control 
In terna t ional  c o m m u n i c a t i o n  
Con t rac to r  c o m m u n i c a t i o n  
Tota l  
10 4 13 22 3 32 9 30  
- 4( ) - 




4 - I1 18 
15 5 14 13 na  na  na  
37 - 20  13 63  16 57 23 67 
re = research  ef fec t iveness ;  ue = user  e f fec t iveness ;  cs  = c i ta t ion  score;  pn  = patent  number ;  dl = d e v e l o p m e n t  length;  o p m  = opera t ing  profi t  ma rg in ;  - var iab le  does  
not  associa te  s igni f icant ly  wi th  the e f fec t iveness  ind ica tor  at i ssue :  ( - )  var iab le  associa tes  nega t ive ly  wi th  the e f fec t iveness  ind ica tor  at issue;  na  = not  appl icab le .  
control also explain (in a strictly statistical sense) 
most of the variance of the industrial effectiveness 
measure, the operating profit margin. The fact that 
process control does not add explained variance to all 
the effectiveness measures in universities and insti- 
tutes or to the industrial effectiveness measure in 
industry is also worth mentioning. 
The model of the citation score in universities, and 
to a lesser extent in institutes, shows a similar pattern 
to that for research effectiveness in universities; but 
both models are weaker, with a total of explained 
variance of 16% and 20%, respectively. The neural 
network models of the innovative effectiveness indi- 
cators show that the frequency of project team meet- 
ings is higher in the case of high effectiveness in the 
discovery phase. A shorter development phase is posi- 
tively associated with the adequacy of resources, the 
importance of short-term, middle-term and long-term 
planning and the attendancy mix, indicating a high 
level of lateral and cross-functional communication. 
8. DISCUSSION AND CONCLUSIONS 
8.1 Comparison of the strata 
Table 6 has shown that great differences occur in 
the average assessment of the different variables of 
management control between the strata. In most cases 
the research units in universities are found at one end 
of the scale and the industrial laboratories at the other 
end, with the institutes taking up an intermediate pos- 
ition. 
Table 8 shows that most of the hypotheses concern- 
ing the differences between strata are confirmed by 
the data. In accordance with the hypothesis of the pro- 
fit or not-for-profit background of the research organi- 
zations, the staff in companies are clearly more posi- 
tive about the factors of system control than their 
colleagues in universities and institutes. The average 
assessment of personnel control and the adequacy of 
the personnel and material resources in industry are 
about 0.8 point higher on a Likert 5-point scale than 
in universities, and 0.2 and 0.6 points higher than in 
institutes. The difference in the assessment of admin- 
istrative control is even larger, about 1.5 points 
between industry and universities and more than 1 
point between industry and institutes. For instance, 
according to the scientific staff of more than 50% of 
the university laboratories, it would take more than a 
year to reallocate a major part of the resources to a 
new research line, while in industrial laboratories the 
average estimation is six months or less. This substan- 
tial difference in the assessment of the variables of 
system control may indicate that, despite the recent 
policy to improve market orientation, fundamental 
differences between profit and not-for-profit organiza- 
tions still exist. 
In accordance with the hypothesis of higher task 
uncertainty, the variables of research process com- 
munication (frequently of research meetings and the 
attendancy mix) are assessed significantly higher in 
universities and institutes than in industrial labora- 
tories. It must be considered, however, that at least 
part of this difference must be attributed to the much 
larger size of the R&D process in industry. 
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TABLE 8. The determined strength of management control compared with the hypotheses 
Universities Institutes Companies Hypothesis 
System control -+ + confirmed 
Process control 
planning -+ -~ + not confirmed 
frequency/attendancy mix + + - confirmed 
External control 
international communication - + + not confirmed 
contractor communication + + * confirmed 
+ comparatively highest strength of the management control variable at issue; + moderate strength; - lowest strength; * not measured. 
In accordance with the expectation, the assessed 
importance of planning by higher management is the 
highest in industry, but the differences are far from 
significant. For universities especially, this result was 
unexpected. Apparently colleague control is more 
accepted than is assumed in literature (Weick, 1979). 
In contrast to expectations, international communi- 
cation turned out to be more intensive in industry than 
in universities and institutes. This contradictory find- 
ing may be explained by the large difference in the 
available travelling budget. 
An alarming result is the negative judgement of the 
system control situation in universities and, though to 
a lower extent, in institutes (see Table 6). For the cor- 
rect interpretation of this result one should remember 
that in a professional bureaucracy, such as a medical 
faculty, there is always a certain tension between pro- 
fessionals and administration (Mintzberg, 1983). This 
may have resulted in unjustified negative judgement 
of the organizational flexibility. Nevertheless, it might 
be an indication of a gradual decrease of organiza- 
tional flexibility of Dutch research organizations due 
to budget retrenchments. These have forced research 
units to acquire additional external funding to such 
an extent that the programmatic continuity may 
become at risk. 
8.2 Comparing high and low performers 
One of the most striking results of this study is that 
the high performers clearly differed from their low 
performing competitors on a number of socio- 
dynamic and system-technical features, regarding 
both organizational flexibility and control capacity. 
Table 9 shows that the management control vari- 
ables-personnel control, administrative control and 
external control--together explain the variance of 
research effectiveness in universities and that of user 
effectiveness in institutes. In constrast to this, the 
management control variables explain no variance of 
user effectiveness in universities, and only personnel 
control explains some of the variance of research 
effectiveness in institutes. Research effectiveness is 
considered to reflect the ability to conduct basic 
research, the primary goal of universities, whereas 
user effectiveness is considered to reflect the ability 
to conduct applied research, the primary goal of insti- 
tutes. Therefore, these results provide confirming evi- 
dence for the hypothesis that robust and consistent 
associations would be found between management 
control and those effectiveness indicators which 
reflect the primary goals, and weak and inconsistent 
associations with those indicators which reflect sec- 
ondary management goals of the research organiza- 
tions. 
The above findings are, to some extent, supported 
by the neural network models of the citation score. 
This indicator is considered to reflect the use of the 
results by scientific colleagues and physicians. Both 
in universities and institutes, personnel control and 
contractor communication explain some of the vari- 
ance of research and user effectiveness, whereas 
administrative control also explains some variance of 
research effectiveness in universities. But the 
resulting models are relatively weak, probably due to 
the inevitable time-lag between publishing and 
citation measurement. 
Interestingly, personnel control, administrative 
control and external control separate the above-aver- 
age from the below-average performers for the indi- 
cator of industrial effectiveness, the operating profit 
margin. In the companies with the greatest operating 
profit margins, the perceived quality of personnel pol- 
icy is much better than in the average companies. In 
addition, the average duration of administrative pro- 
cedures is clearly shorter, and international communi- 
cation with scientists and physicians at congresses and 
workshops is more intense. It can be argued, however, 
that the causality may be the opposite to that which 
has been suggested. The more effective companies are 
also the most profitable and can therefore afford to 
spend more on elaborate laboratory equipment, to 
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TABLE 9. Explained variance of effectiveness by management control for effectiveness indicators which reflect primary or secondary management goals 
Effectiveness indicator Primary goals Secondary goals 
University Institute Company University Institute Company 
Research User Industrial User Research Innovative 
S y s t e m  c o n t r o l  
personnel control + + + 
adequacy - - 
administrative control + + + 
P r o c e s s  c o n t r o l  - - - 
E x t e r n a l  c o n t r o l  + + + 
+ part of the variance of the effectiveness indicator is explained by the management control variable at issue; - no variance explained. 
have more frequent international contacts and can 
have quicker procurement and appointment pro- 
cedures. The R&D staff in the better companies are 
also likely to respond more positively to such studies 
than their colleagues in the less performing compa- 
nies. However, because of the large size of the com- 
panies at issue it may be expected that spending bud- 
gets will not be so much of a bottleneck for 
procurement, appointment and international travel- 
ling. Possibly, the operating profits not only reflect 
the ultimate company goal of maintaining profitabil- 
ity, but also, at least to a certain extent, the contri- 
bution of the R&D function in attaining this goal. This 
would be in accordance with the conclusion drawn by 
van Engelen (1989) for the marketing function. 
If this assumption is correct, in all three strata the 
same management control variables, personnel, 
administrative and external control, are closely asso- 
ciated with effectiveness. This would provide con- 
firming evidence for the main hypothesis, that there 
is a fundamental association between management 
control and effectiveness, dividing the above-average 
from the below-average performers, regardless of the 
organizational setting. It consists of the following fac- 
tors: 
• the perceived effectiveness of personnel policy, a 
socio-dynamic factor of organizational flexibility 
and control capacity combined; 
• the average duration of the administrative pro- 
cedures, a system-technical factor of organizational 
flexibility, For example, it took the best performing 
research laboratories on average 3 to 12 months 
less to reallocate a major part of their resources to 
a new research area; 
• the communication with contractors and inter- 
national communication at conferences and work- 
shops; a socio-dynamic factor combining elements 
of organizational flexibility (e.g. available travel- 
ling budget) and the control capacity of the 
research management. 
Another interesting observation which derives from 
Table 9 is that process control is relatively unimport- 
ant in discriminating between high and low per- 
formers in universities and institutes. Although large 
differences were established in the way and manner 
in which research is supervised, these differences are 
not found in the neural network analysis. For none of 
the effectiveness indicators is variance explained by 
the variables of process control. Apparently, organiza- 
tional flexibility is more prominent in the control mix 
than the control capacity of the research management. 
Tables 7 and 9 show that the operating profit mar- 
gin is not closely related to process control. This is 
not astonishing. The operating profits of a pharma- 
ceutical company may depend on only one or two 
major products, but also on a variety of products. 
Thus a direct relationship between profit performance 
and R&D organization is very unlikely. In contrast 
to this, the innovative effectiveness indicators were 
expected to relate more closely to process control (see 
Section 3). Table 7 shows this to be true. It shows 
that part of the variance of the effectiveness indicator 
for the discovery phase, the patent number, is 
explained by the frequency of project team communi- 
cation. In the structured interviews it became apparent 
that the best performing companies shift their atten- 
tion from the screening of thousands of chemical 
compounds to the understanding of the biochemical 
and physiological background of diseases. The 
screening process itself its becoming increasingly 
automated. According to theory, the growing task 
uncertainty, which derives from this shift from sys- 
tematic screening to fundamental research, will lead 
to a higher informational need (see Section 4) which 
is met by a high frequency of project team meetings. 
More intensive international communication did not 
add explained variance; this is probably due to the 
danger of leakage of confidential information. 
In the relatively certain development phase, a posi- 
tive correlation is found of shorter development 
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length with the assessed importance of strategic, tacti- 
cal and operational planning by top management, and 
the attendancy mix. It indicates the prominent role 
that concurrent engineering (parallel development 
with intensive lateral and cross-functional communi- 
cation in project teams) takes in modern development. 
Reducing time-to-market is essential. As one of the 
research directors put it: "Each day a successful drug 
reaches the market earlier earns $200 000 for the com- 
pany". With this figure in mind, it is obvious how 
great the benefits are for companies that are able to 
shorten the development phase. Concurrent engineer- 
ing practices have so fundamentally changed the phar- 
maceutical R&D process that the current R&D pro- 
cess in the most innovative pharmaceutical companies 
can best be described as a chain of integrated learning 
loops (Janszen, 1994). All pharmaceutical firms make 
use of concurrent engineering. The structured inter- 
views learned that in the above-average performers 
the fine tuning was more precise, and the lateral and 
cross-functional communication more intense. Inter- 
estingly, close monitoring of the development process 
did not go hand-in-hand with a high frequency of pro- 
ject team meetings. Most of the pharmaceutical com- 
panies in this study are multinationals with labora- 
tories in different countries. A high frequency of 
meetings would mean a lot of travelling. Mutual 
adjustment was therefore attained mainly by telecom- 
munication (e-mail and video conferences). In cases 
of very frequent project team meetings, a tendency 
towards ineffectiveness was observed. 
9. MANAGEMENT IMPLICATIONS 
For the correct interpretation of the results 
presented, it should be remembered that all relations 
are of a two-sided causality, because reinforcement 
loops such as doing excellent research, getting inter- 
esting results, attaining more attention of the outside 
world, getting more international contacts, developing 
more innovative ideas etc., are at work here. There- 
fore, the list of features of a high performing research 
laboratory, presented in Table 10, is not meant as a 
blueprint but mainly as a reminder of what is 
important in research management. 
The most important management control variable 
turned out to be personnel control, which explains 
part of the variance of all but one of the effectiveness 
indicators. This is clear confirmation for a central 
thesis in socio-dynamic literature. Stimulating and 
rewarding environments, which enhance the motiv- 
ation of the scientific personnel, are needed for high 
effectiveness. Probably just as interesting is the obser- 
vation that process control did not come out as an 
TABLE 10. Features of high performing research organizations 
Personnel control 
• pay much attention to human resource management and staff motivation 
• use career systems which lead to an inspiring work environment 
• provide many opportunities for attaining recognition 
• try hard to meet the specific needs of the scientific staff 
Adminstrative control 
• are flexible in adapting to changing situations 
• protect their staff against 'red tape' 
• create operating systems which avoid bureaucracy 
• reailocation, appointment and procurement procedures are carried out 
quickly 
External control 
• scan the environment for new ideas, opportunities and financial resources 
• pay much attention to building and maintaining an international R&D 
network 
important factor discriminating between high and low 
performers in universities and institutes. Both ways 
of supervision (tight control, with strict planning of 
every step of the research process, or loose control, 
leaving the individual researcher room for 
manoeuvre) may lead to high effectiveness. There are 
many ways for good research managers to reach their 
goals, but what they cannot change is the inflexibility 
of the organization. Research management and man- 
agement consultants may profit from this knowledge 
by concentrating their efforts on organizational flexi- 
bility. 
Numerous researchers have stressed the importance 
of stimulating and rewarding environments to 
enhance innovative effectiveness. The importance of 
a flexible organization to proactively react to chang- 
ing situations, and the importance of maintaining an 
extensive R&D network, are also stressed in many 
studies. However, until now only limited evidence has 
been presented to prove these statements in the real 
world of management practice. Taking into account 
the large contextual variation, the comparison has 
shown reasonably consistent results. Consequently, 
the findings of this study may be generalized to man- 
agement of innovation and technology management 
at large. 
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Con~61e de gesSon en recherche biom~icale et dans 
I'innovaSon pharmaceuSque 
R~sum~ 
Ce papier fait le point sur les facteurs de gestion 
et d'organisation qui peuvent amrliorer l'efficacit6 de 
la recherche biomrdicale et de l'innovation pharma- 
ceutique. L'r tude consiste en 222 questionnaires 
renvoy6s par l 'encadrement supfrieur scientifique des 
hrpitaux universitaires et des grands instituts de 
recherche mrdicale aux Pays Bas, ainsi que des prin- 
cipaux laboratoires de R&D des socirtrs pharmaceu- 
tiques innovantes en Europe, et en 47 interviews 
approfondies avec des professeurs, des directeurs 
d'instituts et des directeurs de R&D. Les rrsultats 
sugg~rent que les entreprises pharmaceutiques sont 
engagres de faqon plus positive dans un contrrle con- 
tinu que les laboratoires de recherche. Les instituts de 
recherche sur la santr, quant h eux, ont une position 
intermrdiaire. On conclut qu'une combinaison bien 
6quilibrre des contrrles relatifs aux personnels, 
l'administration et aux 6changes extemes est nrces- 
saire pour amrliorer l'efficacit6 des universitrs, des 
instituts et des entreprises, au m~me titre. © 1997 
Elsevier Science Ltd 
Managementkonlxolle yon biomedizinischer Forschung 
und pharmazeutischer InnovaSon 
Abriss 
In dieser Arbeit untersuchen wir Management- und 
Organisationsfaktoren, die die Effektivit~it von biome- 
dizinischer Forschung und pharmazeutischer Inno- 
vation vergrrBem krnnten. Die Studie besteht aus 222 
Fragebrgen, die vom leitenden wissenschaftlichen 
Personal der Universiffitskliniken und der groBen 
Gesundheitsforschungsinstitute in den Niederlanden 
und von den wesentlichen F&Es Labors der innova- 
tiven pharmazeutischen Konzerne in Europa 
beantwortet wurden, und aus 47 umfassenden Inter- 
views mit Professoren, Institutsdirektoren und F&Es 
Direktoren. Die Ergebnisse deuten an, dab sich phar- 
mazeutische Konzerne positiver in konsequenter Kon- 
trolle engagieren als akademische Forschungslabors, 
wobei die Gesundheitsforschungsinstitute eine Zwi- 
schenposition einnehmen. Es wird geschlul3folgert, 
dab eine gut ausgewogene Kombination von Personal, 
Verwaltungs- und externer Kontrolle notwendig ist, 
um die Effektivit~it an Universitaten, Instituten und 
Konzemen gleichermaren zu verbessern. © 1997 
Elsevier Science Ltd 
El ~ de la adminisWad6n de las empres,~ de la 
invesSga~ ~ y de la innovaci~n f a n n a ~  
Resumen 
Se invesfiga en este documento los factores de la 
administraci6n y de la organizaci6n que pueden aumen- 
tar la efectividad de la investigaci6n biomrdica y la 
innovacirn farmacrutica. E1 estudio consiste de un son- 
deo de 222 cuestionarios rellenados por el personal 
cientifico de alto nivel de los hospitales universitarios 
y de los grandes institutos de investigaci6n m&tica en 
los Parses Bajos, a la vez q u e e n  los laboratorios de 
I&D de las empresas de innovaci6n farmacEutica de 
Europa y 47 entrevistas detallados con profesores, 
directores de institutos y gerentes encargados de la 
investigaci6n. Los resultados indican que las empresas 
farmacruticas estfm involucradas m ~  positivamente en 
el control continuo que los laboratorios de investiga- 
ci6n acadEmicos, y que las instituciones de investiga- 
ci6n de la salud toman una posici6n entremedias. Se 
considera que una combinaci6n bien equilibrada de 
control de personal, control administrativo y control 
externo es necesario para mejorar la efectividad, tanto 
en las universidades como en los institutos y en las 
empresas. © 1997 Elsevier Science Ltd 
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